Associated Papers
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
41666166 (PubMed )
Supplement: pone.0339491.s009.xlsx › S4_Table
Clonal Hematopoiesis Associates with Prevalent and Incident Cardiometabolic Disease in High-Risk Individuals.
Regan JA et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
39867361 (PubMed )
Supplement: media-1.xlsx › Supplemental_Table_4
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
36989067 (PubMed )
Supplement: BLOODA_ADV-2022-009564-mmc2.xlsx › SuppTable2
The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.
Pettersson H et al.
Frontiers in Oncology, 2023
37637067 (PubMed )
Supplement: Table_1.xlsx › Supplementary_table_1
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L et al.
Leukemia, 2022
36131041 (PubMed )
Supplement: 41375_2022_1700_MOESM1_ESM.pdf
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
35650444 (PubMed )
Supplement: 41586_2022_4785_MOESM11_ESM.xlsx › historical_growth
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S et al.
Haematologica, 2021
Mutations along a TET2 active site scaffold stall oxidation at 5-hydroxymethylcytosine.
Liu MY et al.
Nature Chemical Biology, 2017
Feature-based classification of amino acid substitutions outside conserved functional protein domains.
Gemovic B et al.
Thescientificworldjournal, 2013
24348198 (PubMed )
Supplement: 948617.f1.pdf
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub FX et al.
Blood, 2010
Select a paper to view details